================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): September 2, 2005
Immunomedics, Inc.
------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
Delaware 000-12104 61-1009366
---------------------------- ------------ -------------------
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Number) Identification No.)
300 American Road, Morris Plains, New Jersey 07950
-------------------------------------------- ----------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (973) 605-8200
Not Applicable
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
ITEM 8.01. OTHER EVENT
On September 2, 2005, Immunomedics, Inc., a Delaware corporation (the
"Company"), received notification from The Nasdaq Stock Market ("Nasdaq")
informing the Company that the Nasdaq Listing and Qualification Panel has
determined that the Company will continue to be listed on The NASDAQ Stock
Market. On September 6, 2005, the Company issued a press release to announce its
receipt of this notification from the NASDAQ. A copy of the press release is
attached hereto as Exhibit 99.1.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits:
99.1 Press release dated September 6, 2005, titled
"Immunomedics Announces Positive Ruling from Nasdaq
Appeal Panel."
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date: September 6, 2005 IMMUNOMEDICS, INC.
By: /s/ Cynthia L. Sullivan
-------------------------------------
Cynthia L. Sullivan
President and Chief Executive Officer
-3-